Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
AMRN
vs
S&P 500
AMRN
S&P 500
Over the past 12 months, AMRN has underperformed S&P 500, delivering a return of -37% compared to S&P 500's +17% growth.
Stocks Performance
AMRN vs S&P 500
Performance Gap
AMRN vs S&P 500
Performance By Year
AMRN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Amarin Corporation PLC
Glance View
Amarin Corporation is a biopharmaceutical company focused on one main prescription medicine, Vascepa, which is a purified omega-3 drug used for certain adults with high triglycerides and elevated cardiovascular risk. In plain terms, it sells a branded heart-health medicine that doctors prescribe to patients who need extra risk reduction beyond diet and standard cholesterol care. The company makes money mainly by selling Vascepa through pharmacies and healthcare distributors, with reimbursement often flowing through insurers and other payers. Its customers are not consumers buying directly off the shelf, but physicians, patients, pharmacies, and health systems that prescribe, stock, and cover the drug. What makes Amarin different is that it is a focused drug company tied to a single specialized product rather than a broad portfolio. Its business depends on medical evidence, regulatory approvals, patent protection, and market access agreements, and it can also use partnerships to reach markets outside its core sales channels.
